# 2026-00629: Florida Pharmacy Loses DEA License Over Unauthorized Drug Orders

2026-00629, Pine Pharmacy; Decision and Order, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-01-15, effective 2026-02-17 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-00629
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-00629
- Title: Pine Pharmacy; Decision and Order
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 1818
- Published: 2026-01-15
- Effective: 2026-02-17
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Florida Pharmacy Loses DEA License Over Unauthorized Drug Orders

## Summary

Pine Pharmacy in Florida lost its DEA registration because it filled risky prescriptions without proper checks and let unauthorized people order controlled drugs. This means Pine Pharmacy can no longer legally handle certain medicines, protecting public safety. The change is effective immediately, so patients and the pharmacy must adjust fast.

## Effects PRIA read

- Immediate Suspension Ordered April 9, 2025: cost, medium. On April 9, 2025, the DEA issued an Order to Show Cause and Immediate Suspension of Registration No. FS1451222 for Pine Pharmacy in Ocala, Florida. The OSC/ISO informed the registrant that the suspension was immediate under 21 U.S.C. 824(d) because the continued registration allegedly presented an…
- Final Revocation and Application Denial: cost, high. The DEA revoked Pine Pharmacy's DEA Certificate of Registration No. FS1451222 and denied any pending applications to renew or modify that registration, as well as any other pending application for additional registration in Florida. The final Order revoking the registration is effective February 17…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-00629 on federalregister.gov](https://www.federalregister.gov/documents/2026/01/15/2026-00629/pine-pharmacy-decision-and-order)
- [2026-00629 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-01-15/pdf/2026-00629.pdf)

## Related
- [Previous: 2026-00627, Jason Vanshaar, M.D.; Decision and Order](https://policyrisk.com/federal-register/2026-00627)
- [Next: 2026-00630, Proposed Collection; Comment Request](https://policyrisk.com/federal-register/2026-00630)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-00629 (as of 2026-06-08).
